AstraZeneca’s Tagrisso Delivers 8-Year Survival in Lung Cancer

Wilmington, Delaware, U.S., September 14, 2026

ADAURA Shows Sustained Overall Survival Benefit

The updated analysis demonstrated a substantial and durable overall survival (OS) benefit with adjuvant osimertinib. In the primary Stage II–IIIA population, an estimated 74% of patients treated with Tagrisso were alive at eight years, compared with 58% of patients receiving placebo. This corresponded to a 47% reduction in the risk of death, with an OS hazard ratio of 0.53 (95% CI, 0.38–0.75). The survival benefit was also maintained across the broader Stage IB–IIIA population. At eight years, an estimated 79% of patients in the Tagrisso group were alive, compared with 64% in the placebo group, representing a 48% reduction in the risk of death (HR 0.52). These findings provide important long-term evidence for osimertinib in the postoperative setting and demonstrate that the treatment benefit observed during earlier ADAURA analyses continues over extended follow-up. The ADAURA findings are particularly significant because early-stage EGFR-mutated NSCLC can recur even after complete surgical removal of the tumor. Adjuvant osimertinib is intended to reduce the likelihood of disease recurrence and improve long-term survival in patients whose tumors carry specific EGFR mutations. The extended follow-up therefore offers clinicians additional evidence regarding the durability of benefit from targeted therapy following surgery.

Phase III Trial Supports Targeted Adjuvant Therapy

ADAURA was a randomized, double-blind, placebo-controlled Phase III clinical trial evaluating osimertinib in patients with completely resected Stage IB–IIIA EGFR-mutated NSCLC. Patients received either once-daily osimertinib or placebo for up to three years, allowing researchers to assess whether postoperative targeted treatment could improve disease outcomes compared with observation. Earlier ADAURA results established a major disease-free survival (DFS) benefit, while the latest analysis focuses on the clinically important endpoint of overall survival after approximately eight years of follow-up. The consistency of the benefit across disease stages and patient subgroups strengthens the evidence supporting osimertinib as an important component of treatment for eligible patients with resected EGFR-mutated NSCLC. The long-term findings also highlight the growing importance of biomarker-driven cancer treatment. Identifying EGFR mutations allows physicians to select patients who may benefit from targeted therapies designed specifically around the molecular characteristics of their tumors. The ADAURA program demonstrates how molecular testing and targeted drug development can influence treatment strategies beyond advanced disease and into earlier stages of cancer.

Long-Term Data Reinforce Tagrisso’s Role

Osimertinib is a third-generation, irreversible EGFR tyrosine kinase inhibitor developed to target EGFR-sensitizing mutations and the T790M resistance mutation, with activity against central nervous system metastases. Its development across different stages of EGFR-mutated NSCLC has made it an important targeted therapy in lung cancer treatment. The eight-year ADAURA survival results provide additional evidence that the benefits of adjuvant osimertinib can persist well beyond the treatment period. For the oncology research community, the findings underscore the value of extended follow-up in Phase III trials, particularly when evaluating therapies intended to prevent recurrence and improve survival after surgery. The results were presented at the IASLC 2026 World Conference on Lung Cancer and published simultaneously in the Journal of Thoracic Oncology. With durable survival benefits demonstrated after long-term follow-up, the ADAURA data further establish the clinical significance of adjuvant osimertinib in EGFR-mutated early-stage NSCLC and represent an important milestone in precision oncology and targeted drug development.

Source: AstraZeneca press release